Clinical effect comparison of different ways of inhaled Budesonide Aerosol in the treatment of children with combined allergic rhinitis and asthma syndrome
CHEN Qiaorong1 LIU Guojun2 LIU Shenghua1 ZHANG Liangjing1 WU Lizhou2
1.Department of Pediatrics, Shenzhen People's Hospital, Guangdong Province, Shenzhen 518109, China; 2.Department of E.N.T, Shenzhen People's Hospital, Guangdong Province, Shenzhen 518109, China
Abstract：[Abstract] Objective To discuss the clinical curative effect of different ways of inhaled Budesonide Aerosol in the treatment of combined allergic rhinitis and asthma syndrome (CARAS) in children. Methods A total of 113 children with mild and moderate CARAS in Department of Pediatrics of Shenzhen People's Hospital form June 2011 to January 2015 were selected as the research objects, and according to random number table method they were divided into group A (39 cases) treated through the mouth inhaled budesonide aerosol, 200 μg/time, 2 times/d; group B (36 cases) treated through the nasally inhaled Budesonide Aerosol, 200 μg/time, 2 times/d; and group C (38 cases) treated through the mouth inhaled Budesonide Aerosol (100 μg/time, 2 times/d) and the nasally inhaled budesonide nasal spray 200 μg/time (each side nasal spray 100 μg each time, 1 time/d); each group were treated for 8 weeks. Correlation parameters of patients in the three groups before and after the treatment were recorded and compared. Results Compared with the group A, the clinical symptom score, pulmonary function, EOS absolute value, and serum total IgE levels of the group B were improved significantly (all P < 0.05), the total effective rate was significantly higher (χ2 = 5.943, P < 0.05); compared the group B with the group C, the difference was not obviously significant (P > 0.05), but the incidence of adverse reactions of group C was significantly higher than the group A and B, and the difference between group B and group C was statistically significant (χ2 = 11.402, P < 0.05). Conclusion The curative effect through the nasally inhaled Budesonide Aerosol, 200 μg/time, 2 times/d (400 μg/d) treated with mild and moderate CARAS is distinct, with less adverse reactions, simple operation, it is worthy of clinical popularization and application.
陈俏容1 刘国钧2 刘胜华1 张良静1 吴枥舟2. 不同途径吸入布地奈德气雾剂治疗儿童过敏性鼻炎哮喘综合征的临床效果对比[J]. 中国医药导报, 2016, 13(3): 110-113.
CHEN Qiaorong1 LIU Guojun2 LIU Shenghua1 ZHANG Liangjing1 WU Lizhou2. Clinical effect comparison of different ways of inhaled Budesonide Aerosol in the treatment of children with combined allergic rhinitis and asthma syndrome. 中国医药导报, 2016, 13(3): 110-113.
[参考文献]
[1] 何佳罕.孟鲁司特联合布地奈德气雾剂吸入治疗支气管哮喘患儿的临床分析[J].临床医药文献电子杂志，2014， 7（3）：115-116.
[2] 郑君芳.布地奈德雾化吸入治疗儿童哮喘的临床疗效分析[J].中国实用医药，2014，33（16）：133-134.
[3] 郭青，孙晓敏，康平.布地奈德雾化吸入治疗儿童咳嗽变异性哮喘[J].中外医疗，2015，11（7）：101-102.
[4] Koray H，Baris U，Hülya A，et al. Nasal and bronchial response to exercise in children with seasonal allergic rhinitis out of the pollen season [J]. Int Forum Allergy Rhinol，2015，5（2）：46-52.
[5] Kew Kayleigh M，Karner C，Mindus Stephanie M，et al. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children [J]. The Cochrane Database of Systematic Reviews，2013，12（15）：901-909.
[6] 袁琛，毛伟，闵芳梅.布地奈德雾化吸入预防肺炎支原体感染诱发儿童哮喘急性发作的疗效观察[J].中华医院感染学杂志，2014，21（11）：243-245.
[7] Vichyanond P，Suratannon C，Lertbunnaphong P，et al. Clinical characteristics of children with non-allergic rhinitis vs with allergic rhinitis [J]. Asian Pacific Journal of Allergy & Immunology，2011，28（4）：270-274.
[8] Cates CJ，Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice （including inhaled steroid maintenance），for chronic asthma in adults and children [J]. The Cochrane Database of Systematic Reviews，2013，4（11）：731-733.
[9] 马红梅，刘香莲.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的作用分析[J].海南医学院学报，2015，8（3）：68-70.
[10] 钟燕，周锦钢，陈锦平，等.沙丁胺醇联合布地奈德治疗咳嗽变异性哮喘的疗效观察[J].实用心脑肺血管病杂志，2013，5（2）：128-130.
[11] 左满凤，舒琼璋，江玲，等.重症毛细支气管炎患儿雾化吸入布地奈德的时机和剂量研究[J].儿科药学杂志，2014， 11（7）：13-16.
[12] 吴莹，黄明夏，陈阳.不同剂量布地奈德吸入治疗小儿哮喘急性发作的对比观察[J].当代医学，2015，7（15）：145-147.
[13] 王晓君，纪英，张莉，等.经鼻吸入布地奈德治疗变应性鼻炎并发支气管哮喘急性发作期49例临床研究[J].陕西医学杂志，2015，4（1）：90-92.
[14] 吴晓静.布地奈德混悬液联合氨溴索雾化吸入治疗毛细支气管炎125例临床观察[J].临床医学，2014，34（6）：110-111.
[15] 李立维.盂鲁司特联合布地奈德治疗咳嗽变异型哮喘的临床观察[J].临床肺科杂志，2015，2（1）：82-84.
[16] 普艳.布地奈德雾化吸入治疗儿童咳嗽变异性哮喘的疗效观察[J].中外医疗，2012，6（2）：119，121.
[17] 李自锋.布地奈德雾化吸入治疗儿童咳嗽变异性哮喘的疗效观察[J].临床合理用药杂志，2011，11（3）：78-79.
[18] 万燕婷.大剂量布地奈德雾化吸入对儿童哮喘的疗效分析[J].中国医药导报，2011，8（3）：69-70.
[19] 刘晓娟，钟文明，罗光亮.布地奈德雾化吸入联合中药方治疗儿童支气管哮喘疗效分析[J].中国妇幼保健，2015， 10（26）：57-59.
[20] 李麒，邓成华，袁伟芳，等.布地奈德联合孟鲁司特钠治疗儿童哮喘的临床研究[J].中国当代医药，2015，22（13）：141-143.
[21] 蔡勇辉，卢浩堂，冯科壬，等.吸入糖皮质激素联合小剂量茶碱与联合白三烯调节剂治疗5岁以下儿童哮喘的效果比较[J].中国当代医药，2014，21（2）：103-106.
[22] 吴小秧，乐高钟，刘素云，等.甲基泼尼松龙治疗5岁以下儿童哮喘的临床分析[J].中国当代医药，2014，21（32）：97-98.
[23] 米娜瓦·阿巴斯，祖木来提·吐尔逊，杨晓红.布地奈德对支气管哮喘患者血清炎症因子及免疫功能的影响[J].海南医学院学报，2015，6（8）：40-42.
京公网安备 11010502046598号